Kuala Lumpur (ANTARA) – Sinovac’s COVID-19 vaccine is very effective in protecting humans from becoming seriously ill, according to research conducted by the Malaysian government.
However, according to the study, vaccines made by Pfizer/BioNTech and AstraZeneca showed a better level of protection.
The latest data improves the position of Sinovac, a Chinese pharmaceutical company whose vaccine efficacy has been in the spotlight.
Sinovac was highlighted after a number of health care workers in Indonesia and Thailand were reported to have contracted the corona virus even though they had been injected with the vaccine.
The research found that 0.011 percent of the approximately 7.2 million people injected with the Sinovac vaccine required treatment in hospital intensive care units (ICUs) due to COVID-19 infection, health officials told reporters Thursday (23/9).
In contrast, the number of Pfizer/BioNTech and AstraZeneca dose injection recipients who were admitted to the ICU due to COVID-19 infection was 0.002 percent and 0.001 percent, respectively.
The research was carried out by the Institute for Clinical Research together with a national task force for handling COVID-19.
Kalaiarasu Peariasamy, director of the Institute for Clinical Research, said that vaccination — with vaccines made by any pharmaceutical company — had reduced people’s risk of being admitted to the ICU by 83 percent.
In addition, he said, vaccination also reduces the risk of death by 88 percent.
That percentage was found in a smaller study involving 1.26 million people.
While in people who had been vaccinated at the full dose, the percentage of those admitted to the ICU was 0.0066 percent, said Dr.
The death rate for people who have been fully vaccinated is also low, at 0.01 percent. Most of them are those who are over 60 years old or who have congenital diseases.
Malaysia has fully vaccinated 58.7 percent of its 32 million population and administered at least one dose of the COVID-19 vaccine to 68.8 percent of the population.